Why the study?
Coronary artery disease remains a major cause of morbidity and mortality, and aortic propagation velocity could serve as a novel, simple echocardiographic index for CAD risk stratification.
Does aortic propagation velocity accurately predict the presence of coronary artery disease?
Does aortic propagation velocity accurately predict the presence of coronary artery disease?
Answers are grounded in this paper and cite their sources.
Aortic propagation velocity is a promising noninvasive echocardiographic index with high sensitivity and specificity for predicting coronary artery disease.
INTRODUCTION: Coronary artery disease (CAD) and its outcome, myocardial infarction, is yet a significant etiology of mortality and morbidity nowadays. The aortic propagation velocity (APV) can be a simple, straightforward and novel echocardiographic index for the risk stratification in the evaluation of CAD. In this meta-analysis, we evaluated the predictive role of APV in CAD. MATERIAL AND METHODS: Relevant electronic bibliographies (PubMed, ScienceDirect, Scopus, EMbase, the Cochrane library) were explored. Related reports were selected according to the inclusion and exclusion criteria. Meta-analysis was performed using the Comprehensive Meta-analysis 2.0 software. RESULTS: Eventually, 5 articles met the inclusion criteria and included in the meta-analysis. Five studies with 490 patients reported the APV mean in CAD and non-CAD groups. A random-effect model was used and the pooled findings demonstrated a significant higher APV in non-CAD group compared to CAD group (SMD: 2.39, 95% CI: 1.70-3.07, P < .001, I2: 84%, Q: 19.03). The diagnostic value of APV in predicting CAD showed 86.3% sensitivity (95% CI: 74-91, P value < .001, I2: 65%, Q: 8.53, P value: .03) and 83.8% specificity (95% CI: 69-94, P value < .001, I2: 60%, Q: 9.89, P value: .01). CONCLUSION: There was a predictive role of APV in CAD with suitable specificity and sensitivity. Moreover, aortic distensibility and aortic strain were significantly different in CAD and non-CAD patients. APV could be used as a good noninvasive tool for screening CAD.
No takes yet. Share an insight, caveat, or question.
Ghaderi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: